Compare Travere Therapeutics Inc. Common Stock (TVTX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs ProShares UltraPro S&P500 — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while ProShares UltraPro S&P500 trades at $148.41 (market cap $5.68B). The key difference: ProShares UltraPro S&P500 is the larger of the two by market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and ProShares UltraPro S&P500 for 30 Days on average.
| TVTX | UPRO | |
|---|---|---|
Market Cap | $4.88B | $5.68B |
Volume | 1,668,577 | 1,616,348 |
Sector | Health | Leveraged / Inverse |
52-Week High | $67.52 | $157.66 |
52-Week Low | $26.79 | $89.29 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UPRO trades at $155.38, showing minimal daily movement with a slight 0.05% decline. The technical outlook remains bullish with strong moving average signals, though oscillators indicate neutral momentum. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment for this leveraged ETF.
As a leveraged S&P 500 ETF, UPRO's performance is tied to broader market movements. Current technical strength supports near-term upside potential, but elevated RSI levels and slowing earnings growth projections for the underlying index present headwinds. The ETF's leveraged structure amplifies both gains and losses, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
